RESUMEN
Mycoplasma pneumoniae (MP) is the cause of Mycoplasma pneumoniae pneumonia (MPP) in children and adolescents, with the clinical manifestations highlighted by intermittent irritating cough, accompanied by headache, fever and muscle pain. This paper aimed to study the research status and focal points in MP infection, especially the common laboratory diagnostic methods and clinical treatment of Mycoplasma pneumoniae. Laboratory diagnostic methods include molecular assay, serological antibody detection, rapid antigen detection and isolation and culture. Polymerase chain reaction (PCR) is the gold standard with high sensitivity and specificity. The serological antibody can detect various immune antibodies qualitatively or quantitatively in serum. Rapid antigen can be detected faster, with no equipment environment requirements, which can be used for the early diagnosis of MP infection. While the culture growth cycle is long and insensitive, not recommended for routine diagnosis. Macrolides were the preferred drug for children with MPP, while the drug resistance rate was rising in China. Tetracycline can be substituted but was not recommended for children under 8 years of age, quinolone drugs are not necessary, severe MPP can be combined with glucocorticoids, involving the nervous or immune system can choose gamma globulin. Other treatments for MPP including symptomatic treatment which can alleviate symptoms, improve lung function and improve prognosis. A safe and effective vaccine needed to be developed which can provide protective immunity to children and will reduce the incidence of MPP.
Asunto(s)
Antibacterianos , Mycoplasma pneumoniae , Neumonía por Mycoplasma , Humanos , Niño , Neumonía por Mycoplasma/diagnóstico , Neumonía por Mycoplasma/tratamiento farmacológico , Mycoplasma pneumoniae/aislamiento & purificación , Mycoplasma pneumoniae/inmunología , Antibacterianos/uso terapéutico , Adolescente , Preescolar , Reacción en Cadena de la Polimerasa , Anticuerpos Antibacterianos/sangre , Macrólidos/uso terapéutico , Antígenos Bacterianos/inmunologíaRESUMEN
The combination of copper-metal organic framework (Cu-MOF) with graphene oxide (GO) has received growing interest in electrocatalysis, energy storage and sensing applications. However, its potential as an electrochemical biosensing platform remains largely unexplored. In this study, we introduce the synthesis of GO/Cu-MOF nanocomposite and its application in the simultaneous detection of two biomarkers associated with lower respiratory infections, marking the first instance of its use in this capacity. The physicochemical properties and structural elucidation of this composite were studied with the support of XRD, FTIR, SEM and electrochemical techniques. The immunosensor was fabricated by drop casting the nanocomposite on dual screen-printed electrodes followed by functionalization with pyrene linker. The covalent immobilization of the monoclonal antibodies of the bacterial antigens of Mycoplasma pneumoniae (M. pneumoniae; M. p.) and Legionella pneumophila (L. pneumophila; L. p.) was achieved using EDC-NHS chemistry. The differential pulse voltammetry (DPV) signals of the developed immunosensor platform demonstrated a robust correlation across a broad concentration range from 1 pg/mL to 100 ng/mL. The immunosensor platform has shown high degree of selectivity against antigens for various respiratory pathogens. Moreover, the dual immunosensor was successfully applied for the detection of M. pneumoniae and L. pneumophila antigens in spiked water samples showing excellent recovery percentages. We attribute the high sensitivity of the immunosensor to the enhanced electrocatalytic characteristics, stability and conductivity of the GO-MOF composite as well as the synergistic interactions between the GO and MOF. This immunosensor offers a swift analytical response, simplicity in fabrication and instrumentation, rendering it an appealing platform for the on-field monitoring of pathogens in environmental samples.
Asunto(s)
Antígenos Bacterianos , Técnicas Biosensibles , Cobre , Técnicas Electroquímicas , Grafito , Legionella pneumophila , Estructuras Metalorgánicas , Mycoplasma pneumoniae , Legionella pneumophila/inmunología , Legionella pneumophila/aislamiento & purificación , Mycoplasma pneumoniae/inmunología , Mycoplasma pneumoniae/aislamiento & purificación , Grafito/química , Técnicas Electroquímicas/métodos , Técnicas Biosensibles/métodos , Cobre/química , Estructuras Metalorgánicas/química , Antígenos Bacterianos/inmunología , Antígenos Bacterianos/análisis , Inmunoensayo/métodos , Microbiología del Agua , Nanocompuestos/químicaRESUMEN
BACKGROUND: Community-acquired pneumonia often stems from the macrolide-resistant strain of Mycoplasma pneumoniae, yet no effective vaccine exists against it. METHODS: This study proposes a vaccine-immunoinformatics strategy for Mycoplasma pneumoniae and other pathogenic microbes. Specifically, dominant B and T cell epitopes of the Mycoplasma pneumoniae P30 adhesion protein were identified through immunoinformatics method. The vaccine sequence was then constructed by coupling with CTLA-4 extracellular region, a novel molecular adjuvant for antigen-presenting cells. Subsequently, the vaccine's physicochemical properties, antigenicity, and allergenicity were verified. Molecular dynamics modeling was employed to confirm interaction with TLR-2, TLR-4, B7-1, and B7-2. Finally, the vaccine underwent in silico cloning for expression. RESULTS: The vaccine exhibited both antigenicity and non-allergenicity. Molecular dynamics simulation, post-docking with TLR-2, TLR-4, B7-1, and B7-2, demonstrated stable interaction between the vaccine and these molecules. In silico cloning confirmed effective expression of the vaccine gene in insect baculovirus vectors. CONCLUSION: This vaccine-immunoinformatics approach holds promise for the development of vaccines against Mycoplasma pneumoniae and other pathogenic non-viral and non-bacterial microbes.
Asunto(s)
Vacunas Bacterianas , Antígeno CTLA-4 , Biología Computacional , Epítopos de Linfocito B , Epítopos de Linfocito T , Mycoplasma pneumoniae , Neumonía por Mycoplasma , Mycoplasma pneumoniae/inmunología , Mycoplasma pneumoniae/genética , Epítopos de Linfocito T/inmunología , Epítopos de Linfocito T/genética , Vacunas Bacterianas/inmunología , Vacunas Bacterianas/genética , Epítopos de Linfocito B/inmunología , Epítopos de Linfocito B/genética , Humanos , Biología Computacional/métodos , Neumonía por Mycoplasma/prevención & control , Neumonía por Mycoplasma/inmunología , Antígeno CTLA-4/inmunología , Simulación de Dinámica Molecular , Simulación del Acoplamiento Molecular , Receptor Toll-Like 2/inmunología , InmunoinformáticaRESUMEN
PURPOSE: The COVID-19 pandemic has notably altered the infection dynamics of various pathogens. This study aimed to evaluate the pandemic's impact on the infection spectrum of Mycoplasma pneumoniae (M. pneumoniae) among children with community acquired pneumonia (CAP). METHODS: We enrolled pediatric CAP patients admitted to a tertiary hospital in southwest China to compare the prevalence and characteristics of M. pneumoniae infections before (2018-2019) and during (2020-2022) the COVID-19 pandemic. Detection of M. pneumoniae IgM antibodies in serum were conducted using either indirect immunofluorescence or passive agglutination methods. RESULTS: The study included 1505 M. pneumoniae-positive and 3160 M. pneumoniae-negative CAP patients. Notable findings were the higher age and frequency of pneumonia-associated symptoms in M. pneumoniae-positive patients, alongside a lower male proportion and fewer respiratory co-infections. The year 2019 saw a notable increase in M. pneumoniae infections compared to 2018, followed by a decline from 2020 to 2022. The COVID-19 pandemic period witnessed significant alterations in age distribution, male proportion, and co-infections with specific pathogens in both M. pneumoniae-positive and negative patients. The M. pneumoniae infections were predominantly seasonal, peaking in autumn and winter during 2018 and 2019. Although there was a sharp drop in February 2020, the infection still peaked in cold months of 2020 and 2021. However, the typical seasonal pattern was nearly absent in 2022. CONCLUSIONS: The COVID-19 pandemic has markedly changed the infection landscape of M. pneumoniae in pediatric CAP patients, with shifts observed in infection rates, demographic profiles, co-infections, and seasonal patterns.
Asunto(s)
COVID-19 , Infecciones Comunitarias Adquiridas , Mycoplasma pneumoniae , Neumonía por Mycoplasma , Centros de Atención Terciaria , Humanos , Infecciones Comunitarias Adquiridas/epidemiología , Infecciones Comunitarias Adquiridas/microbiología , China/epidemiología , Masculino , Neumonía por Mycoplasma/epidemiología , Femenino , COVID-19/epidemiología , Niño , Centros de Atención Terciaria/estadística & datos numéricos , Estudios Retrospectivos , Preescolar , Mycoplasma pneumoniae/inmunología , Lactante , Coinfección/epidemiología , Coinfección/microbiología , Coinfección/virología , Adolescente , SARS-CoV-2 , Prevalencia , Inmunoglobulina M/sangre , HospitalizaciónRESUMEN
A non-pathogenic Mycoplasma pneumoniae-based chassis is leading the development of live biotherapeutic products (LBPs) for respiratory diseases. However, reports connecting Guillain-Barré syndrome (GBS) cases to prior M. pneumoniae infections represent a concern for exploiting such a chassis. Galactolipids, especially galactocerebroside (GalCer), are considered the most likely M. pneumoniae antigens triggering autoimmune responses associated with GBS development. In this work, we generated different strains lacking genes involved in galactolipids biosynthesis. Glycolipid profiling of the strains demonstrated that some mutants show a complete lack of galactolipids. Cross-reactivity assays with sera from GBS patients with prior M. pneumoniae infection showed that certain engineered strains exhibit reduced antibody recognition. However, correlation analyses of these results with the glycolipid profile of the engineered strains suggest that other factors different from GalCer contribute to sera recognition, including total ceramide levels, dihexosylceramide (DHCer), and diglycosyldiacylglycerol (DGDAG). Finally, we discuss the best candidate strains as potential GBS-free Mycoplasma chassis.
Asunto(s)
Glucolípidos , Síndrome de Guillain-Barré , Mycoplasma pneumoniae , Síndrome de Guillain-Barré/microbiología , Mycoplasma pneumoniae/genética , Mycoplasma pneumoniae/inmunología , Humanos , Glucolípidos/metabolismo , Galactosilceramidas , Reacciones Cruzadas , Neumonía por Mycoplasma/microbiología , Neumonía por Mycoplasma/inmunología , Anticuerpos Antibacterianos/sangre , Anticuerpos Antibacterianos/inmunologíaRESUMEN
BACKGROUND: The incidence of atypical pneumonia among immunocompromised patients is not well characterized. Establishing a diagnosis of atypical pneumonia is challenging as positive tests must be carefully interpreted. We aimed to assess the test positivity rate and incidence of atypical pneumonia in transplant recipients. METHODS: A retrospective cohort study was conducted at the Yale New Haven Health System in Connecticut. Adults with solid organ transplant, hematopoietic stem cell transplant (HSCT), or chimeric antigen receptor T-cell, who underwent testing for atypical pathogens of pneumonia (Legionella pneumophilia, Mycoplasma pneumoniae, Chlamydia pneumoniae, and Bordetella pertussis) between January 2016 and August 2022 were included. Positive results were adjudicated in a clinical context using pre-defined criteria. A cost analysis of diagnostic testing was performed. RESULTS: Note that, 1021 unique tests for atypical pathogens of pneumonia were performed among 481 transplant recipients. The testing positivity rate was 0.7% (n = 7). After clinical adjudication, there were three cases of proven Legionella and one case of possible Mycoplasma infection. All cases of legionellosis were in transplant recipients within 1-year post-transplantation with recently augmented immunosuppression and lymphopenia. The possible case of Mycoplasma infection was in an HSCT recipient with augmented immunosuppression. The cost of all tests ordered was $50,797.73. CONCLUSION: The positivity rate of tests for atypical pneumonia was very low in this transplant cohort. An algorithmic approach that targets testing for those with compatible host, clinical, radiographic, and epidemiologic factors, and provides guidance on test selection and test interpretation, may improve the diagnostic yield and lead to substantial cost savings.
Asunto(s)
Huésped Inmunocomprometido , Receptores de Trasplantes , Humanos , Estudios Retrospectivos , Masculino , Persona de Mediana Edad , Femenino , Adulto , Receptores de Trasplantes/estadística & datos numéricos , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Anciano , Trasplante de Órganos/efectos adversos , Incidencia , Mycoplasma pneumoniae/inmunología , Mycoplasma pneumoniae/aislamiento & purificación , Bordetella pertussis/inmunología , Bordetella pertussis/aislamiento & purificación , Chlamydophila pneumoniae/inmunología , Connecticut/epidemiologíaRESUMEN
Introducción: la neumonía por Mycoplasma pneumoniae continúa estando infradiagnosticada en las consultas de Pediatría de Atención Primaria, especialmente en los niños más pequeños. Material y métodos: estudio prospectivo en 9 cupos pediátricos, sobre niños desde 1 mes a 14 años con neumonía diagnosticada mediante radiografía y clínica compatible. Diagnóstico etiológico mediante serología en la fase aguda. Se analiza la relación de diferentes variables con la etiología atípica y no atípica. Resultados: de los 92 pacientes incluidos, un 30,4% fueron neumonías atípicas que, a pesar de no ser raras en menores de 2 años (26% del total a esta edad), predominaron en los mayores de 5 años (80,9%). La edad media en meses fue significativamente mayor en atípicas (74,2 ± 42,2), que en las no atípicas (35,9 ± 33,8; p <0,0001). La congestión nasal (42,8%; OR: 1,8; p <0,01) y la taquipnea (64,2%; OR: 2,4; p <0,014) fueron significativamente más frecuentes en las no atípicas. El patrón alveolar se observó en el 53,6% de las neumonías atípicas, sin diferencias con las no atípicas. Solamente un 25% de las neumonías atípicas fueron correctamente tratadas inicialmente con macrólidos en monoterapia sin existir diferencias en cuanto a su evolución con respecto a la elección de un tipo u otro de terapia antibiótica. Las neumonías no atípicas precisaron antibioterapia intravenosa con una mayor frecuencia (15,6%) de forma no estadísticamente significativa. Conclusión: las neumonías por gérmenes atípicos parecen más prevalentes en niños pequeños de lo previamente descrito, en ocasiones en coexistencia con virus. Su mejor diagnóstico y tratamiento continúan siendo un reto por resolver (AU)
Introduction: pneumonia caused by Mycoplasma pneumoniae continues to be underdiagnosed in paediatric primary care, especially in younger children.Material and methods: prospective study conducted in 9 primary care paediatric caseloads, including children aged 1 month to 14 years with pneumonia diagnosed based on compatible radiographic findings and clinical features. The aetiological diagnosis was made by acute-phase serological testing. We analysed the association of different variables with atypical and typical aetiologies.Results: of the 92 patients in the sample, 30.4% had atypical pneumonias which, while not rare in children under 2 years (26%) predominated in children over 5 years (80.9%). The mean age in months was significantly higher in cases with an atypical (74.2±42.2) versus typical (35.9±33.8) aetiology (p<0.0001). Nasal congestion (42.8%; OR 1.8; p<0.01) and tachypnoea (64.2%; OR 2.4; p<0.014) were significantly more frequent in typical pneumonia. The alveolar pattern was observed in 53.6% of atypical pneumonias, with no differences compared to typical pneumonias. Only 25% of atypical pneumonia cases were treated correctly with first-line macrolide monotherapy, with no differences in outcomes based on the choice of antibiotherapy. Patients with typical pneumonia required intravenous antibiotic therapy more frequently (15.6%), but the difference was not statistically significant.Conclusion: atypical germs were more frequent at younger ages than previously described, in some cases with concomitant detection of viruses. Improving the diagnosis and treatment of atypical pneumonia remains a challenge. (AU)
Asunto(s)
Humanos , Recién Nacido , Lactante , Preescolar , Niño , Adolescente , Atención Primaria de Salud , Neumonía por Mycoplasma/diagnóstico , Mycoplasma pneumoniae/inmunología , Ensayo de Inmunoadsorción Enzimática , Neumonía por Mycoplasma/tratamiento farmacológico , Antibacterianos/uso terapéutico , Estudios ProspectivosRESUMEN
Mycoplasma pneumoniae (Mp) residing extracellularly in the respiratory tract is the primary cause of bacterial community-acquired pneumonia in humans. However, the detailed pathological mechanism of Mp infection, especially inflammation in the lung, remains unclear. This study examined the role of the neutrophils in the inflammation of Mp-induced pneumonia in mice and the mechanism of neutrophil infiltration into the lungs in the Mp-induced pneumonia. We observed massive infiltration of neutrophils in the bronchoalveolar lavage fluid (BALF) and lung injury after the Mp challenge. The neutrophils were shown to contribute to lung injury in Mp pneumonia but were not involved in eliminating Mp, suggesting that neutrophils are detrimental to the host in Mp pneumonia. Mp also induced the production of inflammatory cytokines and chemokines in the BALF in a toll-like receptor 2 (TLR2)-dependent manner. Particularly, both interleukin (IL)-1α and IL-12 p40 played a crucial role in neutrophil infiltration into the BALF in a coordinated manner. Both IL-1α and IL-12 p40 were released from the alveolar macrophages depending on the TLR2 and reactive oxygen species. In addition, the community-acquired respiratory distress syndrome (CARDS) toxin from Mp were found to induce neutrophil infiltration into BALF in a TLR2-independent and IL-1α-dependent manner. Collectively, the TLR2-dependent production of both IL-1α and IL-12 p40, and CARDS toxin have been elucidated to play an important role in neutrophil infiltration into the lungs subsequently leading to the lung injury upon Mp infection in mice. These data will aid in the development of therapeutics and vaccines for Mp pneumonia. IMPORTANCE Although Mp-induced pneumonia is usually a self-limiting disease, refractory life-threatening pneumonia is often induced. In addition, the development of alternative therapeutic strategies for Mp is expected because of the emergence of antibiotic-resistant Mp. However, the lack of knowledge regarding the pathogenesis of Mp-induced pneumonia, especially inflammation upon the Mp infection, makes it tedious to design novel therapeutics and vaccines. For example, although neutrophil infiltration is widely recognized as one of the characteristics of Mp-induced pneumonia, the precise role of neutrophils in the aggravation of Mp pneumonia remains unclear. This study showed that the infiltration of neutrophils in the lungs is detrimental to the host in Mp-induced pneumonia in mice. Furthermore, the TLR2-dependent IL-1α and IL-12 p40 production, and CARDS toxin play important roles in neutrophil infiltration into the lung, following lung injury. Our findings apply to the rational design of novel therapeutics and vaccines against Mp.
Asunto(s)
Proteínas Bacterianas/inmunología , Toxinas Bacterianas/metabolismo , Interleucina-12/metabolismo , Interleucina-1alfa/metabolismo , Lesión Pulmonar/inmunología , Neutrófilos/inmunología , Neumonía por Mycoplasma/inmunología , Receptor Toll-Like 2/metabolismo , Animales , Líquido del Lavado Bronquioalveolar , Inflamación/inmunología , Inflamación/patología , Pulmón , Lesión Pulmonar/patología , Macrófagos Alveolares/inmunología , Ratones , Mycoplasma pneumoniae/inmunología , Infiltración Neutrófila , Especies Reactivas de Oxígeno , Síndrome de Dificultad Respiratoria/inmunología , Receptor Toll-Like 2/genéticaRESUMEN
BACKGROUND: Mycoplasma pneumoniae (M. pneumoniae) is implicated in several immune-mediated extrapulmonary manifestations, including reactive arthritis. Recently, increased total serum IgE were reported in children developing M. pneumoniae-related extrapulmonary diseases (MpEPDs). Here, we aimed at analyzing these aspects in children affected with rheumatic disorders and, in detail, Juvenile Idiopathic Arthritis (JIA). METHODS: M. pneumoniae serology (IgG and IgM) and total serum IgE were concomitantly analyzed in 139 pediatric patients diagnosed with: JIA (Group 1, n = 85), or any rheumatic disease other than JIA (Group 2, n = 27), or non-inflammatory endocrinological disorders (Group 3, n = 27). RESULTS: Overall, 19.4% M. pneumoniae seroprevalence was observed in this hospitalized pediatric population, without signicant differences among the three groups. No significant differences in total serum IgE levels were noted among these groups; however, a second analysis excluding children with very high (and clearly abnormal) IgE levels suggested that JIA patients and, in detail, those with oligopolyarticular forms may have higher serum IgE concentrations. This relative difference among groups in serum IgE level seems to be more pronounced in M. pneumoniae seropositive children. CONCLUSIONS: M. pneumoniae infection should be actively sought in children developing immune-mediated diseases, including patients affected with JIA and, especially, in oligopolyarticular forms. There is some evidence that total serum IgE levels may tend to be increased in patients with oligopolyarticular JIA subtype and especially in those resulting as M. pneumoniae seropositive. However, further and focused research is needed to confirm these preliminary results and to clarify the relation between M. pneumoniae infection, atopic status, and immune-mediated arthritis.
Asunto(s)
Anticuerpos Antibacterianos/sangre , Artritis Juvenil/microbiología , Inmunoglobulina E/sangre , Mycoplasma pneumoniae/aislamiento & purificación , Neumonía por Mycoplasma/epidemiología , Anticuerpos Antibacterianos/inmunología , Artritis Juvenil/sangre , Artritis Juvenil/inmunología , Niño , Preescolar , Estudios Transversales , Femenino , Humanos , Inmunoglobulina E/inmunología , Lactante , Recién Nacido , Masculino , Mycoplasma pneumoniae/inmunología , Neumonía por Mycoplasma/sangre , Neumonía por Mycoplasma/inmunología , Neumonía por Mycoplasma/microbiología , Estudios SeroepidemiológicosRESUMEN
Mycoplasma genitalium and M. pneumoniae are two significant mycoplasmas that infect the urogenital and respiratory tracts of humans. Despite distinct tissue tropisms, they both have similar pathogenic mechanisms and infect/invade epithelial cells in the respective regions and persist within these cells. However, the pathogenic mechanisms of these species in terms of bacterium-host interactions are poorly understood. To gain insights on this, we infected HeLa cells independently with M. genitalium and M. pneumoniae and assessed gene expression by whole transcriptome sequencing (RNA-seq) approach. The results revealed that HeLa cells respond to M. genitalium and M. pneumoniae differently by regulating various protein-coding genes. Though there is a significant overlap between the genes regulated by these species, many of the differentially expressed genes were specific to each species. KEGG pathway and signaling network analyses revealed that the genes specific to M. genitalium are more related to cellular processes. In contrast, the genes specific to M. pneumoniae infection are correlated with immune response and inflammation, possibly suggesting that M. pneumoniae has some inherent ability to modulate host immune pathways.
Asunto(s)
Células Epiteliales/microbiología , Mycoplasma genitalium/patogenicidad , Mycoplasma pneumoniae/patogenicidad , Transcriptoma , Células Epiteliales/inmunología , Células Epiteliales/metabolismo , Perfilación de la Expresión Génica , Redes Reguladoras de Genes , Células HeLa , Interacciones Huésped-Patógeno , Humanos , Mycoplasma genitalium/inmunología , Mycoplasma pneumoniae/inmunología , Mapas de Interacción de Proteínas , RNA-Seq , Transducción de Señal , Secuenciación del ExomaRESUMEN
Mycoplasma pneumoniae-induced pneumonia (MPP) is a common cause of community-acquired respiratory tract infections, increasing risk of morbidity and mortality, in children. However, diagnosing early-stage MPP is difficult owing to the lack of good diagnostic methods. Here, we examined the protein profile of bronchoalveolar lavage fluid (BALF) and found that S100A8/A9 was highly expressed. Enzyme-linked immunosorbent assays used to assess protein levels in serum samples indicated that S100A8/A9 concentrations were also increased in serum obtained from children with MPP, with no change in S100A8/A9 levels in children with viral or bacterial pneumonia. In vitro, S100A8/A9 treatment significantly increased apoptosis in a human alveolar basal epithelial cell line (A549 cells). Bioinformatics analyses indicated that up-regulated S100A8/A9 proteins participated in the interleukin (IL)-17 signaling pathway. The origin of the increased S100A8/A9 was investigated in A549 cells and in neutrophils obtained from children with MPP. Treatment of neutrophils, but not of A549 cells, with IL-17A released S100A8/A9 into the culture medium. In summary, we demonstrated that S100A8/A9, possibly released from neutrophils, is a new potential biomarker for the clinical diagnosis of children MPP and involved in the development of this disease through enhancing apoptosis of alveolar basal epithelial cells.
Asunto(s)
Células Epiteliales Alveolares/metabolismo , Apoptosis , Calgranulina A/metabolismo , Calgranulina B/metabolismo , Interleucina-17/farmacología , Mycoplasma pneumoniae/patogenicidad , Neutrófilos/efectos de los fármacos , Comunicación Paracrina , Neumonía por Mycoplasma/metabolismo , Células A549 , Células Epiteliales Alveolares/inmunología , Células Epiteliales Alveolares/microbiología , Células Epiteliales Alveolares/patología , Biomarcadores/metabolismo , Estudios de Casos y Controles , Niño , Preescolar , Femenino , Interacciones Huésped-Patógeno , Humanos , Lactante , Masculino , Mycoplasma pneumoniae/inmunología , Neutrófilos/inmunología , Neutrófilos/metabolismo , Neutrófilos/microbiología , Neumonía por Mycoplasma/inmunología , Neumonía por Mycoplasma/microbiología , Neumonía por Mycoplasma/patología , Transducción de SeñalRESUMEN
OBJECTIVE: Mycoplasma pneumoniae (M. pneumoniae), an extracellular pathogen lacking a cell wall, causes respiratory infection in adults and children and has been implicated in asthma exacerbation; immunoglobulin (Ig) E may be involved in these exacerbations. Specific IgM and IgG immune response to M. pneumoniae has been reported, but less is known about IgE M. pneumoniae antibody (Ab) responses in asthma. Previous studies in our laboratory demonstrated that asthmatic children have increased IgM M. pneumoniae levels, but not IgE. Thus, we sought to investigate whether past M. pneumoniae infection triggers production of M. pneumoniae-specific IgE Abs in adult subjects with/without asthma. METHODS: M. pneumoniae- IgE and -IgM Ab responses were studied in adult asthmatic (N=22) and non-asthmatic (N=22) subjects (ELISA). Data are reported as antibody index. Threshold detection levels: IgE, IgM: 0.2, 0.9, respectively. RESULTS: M. pneumoniae-IgE Ab levels were low and below the threshold of detection in both asthmatic and non-asthmatics (0.002±0.008 vs. 0.02±0.03; P=0.021). However, specific-IgM levels were slightly higher in non-asthmatics compared with asthmatics (0.96±0.37 vs. 0.79±0.31; P=0.054). M. pneumoniae-IgM Ab positivity was similar in both groups (P=1.0). CONCLUSION: IgM M. pneumoniae Abs may play an important role in non-asthma and persist for months after acute infection. IgE M. pneumoniae Abs may play a less important role in both groups.
Asunto(s)
Anticuerpos Antibacterianos/sangre , Asma/inmunología , Inmunoglobulina E/inmunología , Inmunoglobulina M/sangre , Mycoplasma pneumoniae/inmunología , Neumonía por Mycoplasma/inmunología , Adulto , Anticuerpos Antibacterianos/inmunología , Asma/sangre , Asma/complicaciones , Asma/epidemiología , Estudios de Casos y Controles , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , New York/epidemiología , Neumonía por Mycoplasma/sangre , Neumonía por Mycoplasma/epidemiología , Neumonía por Mycoplasma/etiología , PronósticoRESUMEN
Mycoplasma pneumoniae (MP) is a common pathogen that can cause respiratory infections. MP pneumonia (MPP) leads to numerous complications, including lung injury and even death. The present study aimed to investigate the protective effects of Baicalin treatment on MP infectioninduced lung injury and the molecular mechanism underlying these effects. Briefly, after mice were infected intranasally by MP and treated with Baicalin (80 mg/kg), serum levels of MPimmunoglobulin M (IgM) were detected by ELISA. The expression levels of Creactive protein (CRP) in lung tissue were detected by immunohistochemistry and the bronchoalveolar lavage fluid (BALF) was examined by ELISA. Inflammatory factors and inflammatory cells in the BALF were assessed. The expression levels of microRNA (miR)221 in lung tissue were examined by reverse transcriptionquantitative PCR and pathological changes in lung tissue were detected by H&E staining. Cell apoptosis was evaluated by TUNEL assay and the protein expression levels of TLR4, MyD88 and NFκB were detected by western blotting. Baicalin treatment significantly reduced serum levels of MPIgM and CRP expression in lung tissue during MP infection. In addition, Baicalin decreased the levels of IL1ß, IL6, IL18 and TNFα in the BALF, and the number of inflammatory cells. Baicalin also reduced the inflammatory infiltration in lung tissue induced by MP infection, improved the pathological changes detected in lung tissue, reduced apoptosis, and downregulated the protein expression levels of TLR4, MyD88 and NFκB. Furthermore, Baicalin treatment downregulated the expression of miR221 and the protective effects of Baicalin were attenuated by miR221 overexpression. In conclusion, Baicalin has a therapeutic effect on mice with MP infectioninduced lung injury, which may be related to inhibition of miR221 expression and regulation of the TLR4/NFκB signaling pathway.
Asunto(s)
Antiinfecciosos/farmacología , Flavonoides/farmacología , Lesión Pulmonar/tratamiento farmacológico , MicroARNs/genética , Neumonía por Mycoplasma/tratamiento farmacológico , Transducción de Señal/efectos de los fármacos , Animales , Antiinfecciosos/uso terapéutico , Apoptosis/efectos de los fármacos , Líquido del Lavado Bronquioalveolar/inmunología , Proteínas Portadoras/metabolismo , Citocinas/inmunología , Modelos Animales de Enfermedad , Regulación hacia Abajo/efectos de los fármacos , Femenino , Flavonoides/uso terapéutico , Inmunoglobulina M/sangre , Lesión Pulmonar/etiología , Lesión Pulmonar/patología , Ratones Endogámicos BALB C , MicroARNs/efectos de los fármacos , Mycoplasma pneumoniae/efectos de los fármacos , Mycoplasma pneumoniae/inmunología , Factor 88 de Diferenciación Mieloide/metabolismo , FN-kappa B/antagonistas & inhibidores , FN-kappa B/metabolismo , Neumonía por Mycoplasma/complicaciones , Receptor Toll-Like 4/antagonistas & inhibidores , Receptor Toll-Like 4/metabolismoRESUMEN
Mycoplasmas are the smallest and simplest bacteria that lack a cell wall but have the capability of self-replication. Among them, Mycoplasma pneumoniae is one of the most common causes of community-acquired pneumonia. The hallmark of mycoplasma respiratory diseases is the persistence of lung inflammation that involves both innate and adaptive immune responses. In recent years, a growing body of evidence demonstrates that IL-17 plays an important role in respiratory mycoplasma infection, and associates with the pathologic outcomes of infection, such as pneumonitis and asthma. Numerous studies have shown that a variety of cells, in particular Th17 cells, in the lung can secrete IL-17 during respiratory mycoplasma infection. In this article, we review the biological functions of distinct IL-17-producing cells in mycoplasma respiratory infection with a focus on the effect of IL-17 on the outcomes of infection.
Asunto(s)
Interleucina-17/inmunología , Infecciones por Mycoplasma/inmunología , Mycoplasma pneumoniae/inmunología , Infecciones del Sistema Respiratorio/inmunología , Animales , Asma/inmunología , Humanos , Pulmón/inmunología , Neumonía/inmunologíaRESUMEN
A male individual aged 18 years with no significant past medical history presented with fever, headache, dry cough, and chest pain. On clinical examination, he had tachycardia and hypotension needing intravenous fluid resuscitation and inotropic support. A chest radiograph revealed streaky lung opacities, and he was treated with antibiotics for suspected community-acquired pneumonia complicated by septic shock. Significant elevation of cardiac enzymes was noted, and there was a continued need for inotropes to maintain normotension. He also developed intermittent bradycardia, with serial electrocardiograms showing first-degree atrioventricular block, low-voltage QRS complexes, and ST-T wave changes and telemetry demonstrating junctional and ventricular escape rhythm. A complete workup for sepsis and acute myocarditis were performed to find the etiologic agent. Intravenous immunoglobulins were started to treat myocarditis, with eventual clinical improvement. He was eventually diagnosed with an unusual etiology for his illness. He was noted to still have intermittent ventricular escape rhythm on electrocardiograms on follow-up 2 weeks after discharge but continues to remain asymptomatic and in good health.
Asunto(s)
Mycoplasma pneumoniae/aislamiento & purificación , Miocarditis/microbiología , Neumonía por Mycoplasma/diagnóstico , Adolescente , Arritmias Cardíacas/etiología , Bradicardia/diagnóstico , Bradicardia/fisiopatología , COVID-19/diagnóstico , COVID-19/terapia , Diagnóstico Diferencial , Fiebre/etiología , Humanos , Hipotensión/etiología , Inmunoglobulinas Intravenosas/uso terapéutico , Masculino , Mycoplasma pneumoniae/inmunología , Neutropenia/etiología , Neumonía por Mycoplasma/complicaciones , Choque Séptico/microbiología , Taquicardia/etiologíaRESUMEN
Mycoplasma pneumoniae is the most common pathogen of community-acquired pneumonia in humans. Due to its high rates of antibiotic resistance, vaccination has become the best method to control the dissemination of M. pneumoniae. The recombinant carboxyl terminus of the P1 (P1C) protein is an immunodominant antigen, but it has negative effects such as poor stability and lower purity. In the current study, T-B epitopes of the P1C protein were predicted according to bioinformatics analysis and assessed for efficacy in peptide vaccination. BALB/c mice were subcutaneously inoculated with the T-B epitope peptides four times and then infected with M. pneumoniae through the respiratory tract. The results showed that the T-B epitope peptides of the P1C protein (P1C103-117, P1C155-169, P1C224-238 and P1C244-258) induced strong antigen-specific serum antibody responses and cellular immune responses with high levels of serum IgG, IgA antibodies and Th1-biased (IFN-γ and IL-2) cytokines. Immunization with T-B epitope peptides significantly reduced the M. pneumoniae burden and the degree of inflammation in the challenged mice. Furthermore, the levels of IFN-γ and TNF-α in the supernatants of lung homogenates were observably reduced compared to those in the PBS group. Overall, our findings demonstrate that T-B epitopes (P1C103-117, P1C155-169, P1C224-238 and P1C244-258) play significant roles in the P1C protein and can be used to induce powerful humoral and cellular immune responses to provide significant protection against M. pneumoniae pulmonary infection, which provides new insight into the design of potential multiepitope vaccines to prevent host infection by M. pneumoniae.
Asunto(s)
Epítopos de Linfocito B/inmunología , Epítopos de Linfocito T/inmunología , Mycoplasma pneumoniae/inmunología , Péptidos/inmunología , Neumonía por Mycoplasma/inmunología , Animales , Anticuerpos Antibacterianos/inmunología , Antígenos Bacterianos/inmunología , Vacunas Bacterianas/administración & dosificación , Vacunas Bacterianas/inmunología , Modelos Animales de Enfermedad , Ratones , Ratones Endogámicos BALB C , Neumonía por Mycoplasma/microbiología , Neumonía por Mycoplasma/prevención & control , Infecciones del Sistema Respiratorio/inmunología , Infecciones del Sistema Respiratorio/microbiología , Infecciones del Sistema Respiratorio/prevención & controlRESUMEN
ABSTRACT: Community acquired-pneumonia (CAP) has varying causative pathogens and clinical characteristics. This study investigated the prevalence of Mycoplasma pneumoniae (M pneumoniae) and evaluated the clinical characteristics in infected hospitalized children by disease severity.From throat swabs of hospitalized children (5 months to 14 years) with CAP collected between November 2017 and May 2018, M pneumoniae and other CAP pathogens were identified using polymerase chain reaction (PCR). Differences in clinical and laboratory test data were compared between severe and mild case groups.Of 333 hospitalized children enrolled, 221/333 (66.4%) tested positive for M pneumoniae and 24/221 (10.9%) patients were (nâ=â9, aged <5 years vs nâ=â15, ≥5 years) single infection by PCR, however, only 170/333 (51.1%) patients were presented with M pneumoniae IgM-positive. M pneumoniae detection rate by PCR was higher than by immunoglobulin (IgM) serology. In 123/221 (55.7%) M pneumoniae infected patients, coinfection with bacterial pathogens (nâ=â61, <5 years vs nâ=â62, ≥5 years) occurred. Children (aged 3-8 years) had most M pneumoniae infection. Severe M pneumoniae pneumonia (MPP) in children occurred mostly in older age (7 [interquartile ranges {IQR}, 6-8] years; Pâ<â.0001), with longer cough days (14 [IQR, 10-19.5] days; Pâ=â.002) and hospitalization duration (9.5 [IQR, 7-12.3] days; Pâ<â.0001), lower lymphocyte ratio (24.1, [IQR, 20.0-31.1] %; Pâ=â.001), higher neutrophils ratio (66.0, [IQR, 60.2-70.3]%; Pâ<â.0001), and serum C-reactive protein (CRP) level (3.8, [IQR, 1.3-10.9]âmg/L; Pâ=â.027).M pneumoniae is the most commonly detected pathogen in CAP. High coinfection prevalence increases diagnosis difficulty by clinically nonspecific characteristics. M pneumoniae detection by PCR with IgM may improve precise and reliable diagnosis of community-acquired MPP.
Asunto(s)
Niño Hospitalizado/estadística & datos numéricos , Infecciones Comunitarias Adquiridas/epidemiología , Mycoplasma pneumoniae/aislamiento & purificación , Neumonía por Mycoplasma/epidemiología , Adolescente , Anticuerpos Antibacterianos/sangre , Anticuerpos Antibacterianos/inmunología , Niño , Preescolar , China/epidemiología , Infecciones Comunitarias Adquiridas/microbiología , Femenino , Humanos , Inmunoglobulina M/sangre , Inmunoglobulina M/inmunología , Lactante , Masculino , Mycoplasma pneumoniae/inmunología , Neumonía por Mycoplasma/microbiología , Reacción en Cadena de la Polimerasa , PrevalenciaRESUMEN
BACKGROUND: Recently, many cases of pneumonia in children with Mycoplasma pneumoniae infection have been shown to have varying degrees of intrabronchial mucus plug formation. The clinical, laboratory, radiological characteristics, and treatment of patients with Mycoplasma infection are analyzed in this study. The risk factors for M. pneumoniae pneumonia (MPP) mucus plug formation in children are explored, and a risk factor scoring system is established. METHODS: MPP patients treated with bronchoscopy were retrospectively enrolled in the study from February 2015 to December 2019. The children were divided into a mucus plug group and a control group according to the presence or absence of mucus plug formation. The clinical, laboratory, radiological characteristics, and treatment of the two groups of children were compared. Univariate and multivariate logistic regression models were used to identify the risk factors for MPP mucus plug formation. The receiver operating characteristic (ROC) curve was drawn to evaluate the regression model and establish the MPP mucous plug risk factor scoring system. RESULTS: A univariate analysis showed that the children in the mucous group were older and had a longer fever duration, longer hospital stay, higher fever peak, more cases of wheezing symptoms and allergies, and azithromycin or corticosteroids were administered later. In addition, neutrophil, C-reactive protein (CRP), lactate dehydrogenase (LDH), D-dimer (DD), sputum MP-DNA copy number, and total immunoglobulin A (IgA) levels were higher, while prealbumin (PA) levels were lower. The ROC curve analysis showed that children with MPP had PA ≤144.5 mg/L, had used corticosteroids during the course of the illness of ≥4.5 days, CRP ≥12.27 mg/L, an LDH ≥ 462.65 U/L, and there was a possibility of intra-airway mucus formation. The independent risk factors were scored according to their odds ratio (OR) value. Among the 255 children with MPP, the high-risk group had 44 (83.02%) mucus plugs out of 53; the middle-risk group had 35 (34.3%) mucus plugs out of 102; and the low-risk group had 11 (11%) mucus plugs out of 100. CONCLUSIONS: PA levels, timing of corticosteroid use (use in the first few days), CRP levels, and LDH levels were independent risk factors for MPP mucus plug formation. This provides a basis for the early identification of MPP in children combined with mucus plug formation.
Asunto(s)
Bronquios/fisiopatología , Broncoscopía/métodos , Moco/metabolismo , Mycoplasma pneumoniae/genética , Mycoplasma pneumoniae/inmunología , Neumonía por Mycoplasma/fisiopatología , Neumonía por Mycoplasma/cirugía , Corticoesteroides/uso terapéutico , Proteína C-Reactiva/análisis , Niño , Preescolar , Femenino , Fiebre , Productos de Degradación de Fibrina-Fibrinógeno/análisis , Humanos , Lactante , L-Lactato Deshidrogenasa/sangre , Tiempo de Internación , Modelos Logísticos , Masculino , Neutrófilos/metabolismo , Neumonía por Mycoplasma/diagnóstico , Neumonía por Mycoplasma/tratamiento farmacológico , Prealbúmina/análisis , Curva ROC , Estudios Retrospectivos , Factores de RiesgoRESUMEN
OBJECTIVE: Cerebral microbleeds (CMBs) is a subtype of cerebral small vessel disease. Their underlying pathogenesis remains unclear. The aim of this study was to investigate the association between infectious burden (IB) and CMBs. METHODS: Seven hundred and seventy-three consecutive patients who were hospitalized in the Department of Neurology in General Hospital of Western Theater Command without severe neurological symptoms were recruited and selected in this pilot cross-sectional study. CMBs were assessed using the susceptibility-weighted imaging sequence of magnetic resonance imaging. Immunoglobulin G antibodies against common pathogens, including herpes simplex virus (HSV)-1, HSV-2, cytomegalovirus (CMV), Chlamydia pneumoniae (C. pneumoniae), Mycoplasma pneumoniae (M. pneumoniae), Epstein-Barr virus (EBV), Helicobacter pylori (HP), and Borrelia burgdorferi (B. burgdorferi), were measured by commercial ELISA assays. IB was defined as a composite serologic measure of exposure to these common pathogens. RESULTS: Patients with and without CMBs were defined as the CMBs group (n = 76) and the non-CMBs group (n = 81), respectively. IB was significantly different between the CMBs and non-CMBs groups. After adjusted for other risk factors, the increased IB was independently associated with the presence of CMBs (P = 0.031, OR = 3.00, 95% CI [1.11-8.15]). IB was significantly positively associated with the number of CMBs (Spearman ρ = 0.653, P < 0.001). The levels of serum inflammatory markers were significantly different between the CMBs and non-CMBs groups and among the categories of IB. INTERPRETATION: IB consisting of HSV-1, HSV-2, CMV, C. pneumoniae, M. pneumoniae, EBV, HP, and B. burgdorferi was associated with CMBs. All the findings suggested that pathogen infection could be involved in the pathogenesis of CMBs.